BREO ELLIPTA Market Summary

Key Factors Driving BREO ELLIPTA Growth

1. Strong differentiation through once-daily dosing convenience

A major commercial driver for BREO ELLIPTA is its once-daily dosing profile, which differentiates it from many twice-daily ICS/LABA competitors. GSK positioned BREO as a simplified maintenance therapy designed to improve adherence in chronic respiratory diseases where poor compliance remains a major issue. The FDA approval for COPD highlighted its role as a once-daily maintenance treatment that also reduces COPD exacerbations.

2. Large and expanding asthma and COPD patient population

BREO benefits from exposure to two of the world’s largest chronic respiratory disease markets. GSK noted during the asthma approval that nearly 19 million adults in the U.S. alone had asthma, while COPD affects hundreds of millions globally. Rising pollution exposure, smoking-related lung disease, urbanization, and aging populations continue to expand demand for long-term maintenance inhalers.

3. Rapid historical sales growth validated strong physician adoption

BREO ELLIPTA demonstrated significant early commercial uptake after launch. GSK reported that total Relvar/Breo Ellipta sales surpassed £1.0 billion annually during the product’s expansion phase, with U.S. sales alone exceeding £600 million in certain reporting periods. In another quarterly update, GSK reported Relvar/Breo sales growth of 13% year over year to £333 million, driven by continued market-share gains across major markets.

4. Growth supported by the broader ELLIPTA inhaler ecosystem

BREO is strategically important within GSK’s ELLIPTA respiratory platform, which also includes INCRUSE, ANORO, TRELEGY, and ARNUITY. Physician familiarity with the ELLIPTA dry-powder inhaler supports cross-product prescribing and strengthens franchise loyalty. GSK reported that all ELLIPTA products continued gaining U.S. market share during the portfolio’s expansion years, helping offset declining Advair/Seretide sales.

5. Extensive clinical-development program strengthened physician confidence

BREO’s approvals were supported by large clinical-development programs involving thousands of patients. GSK stated that the asthma clinical program included more than 12,000 subjects across 23 studies, while the COPD program involved over 7,800 patients. The breadth of efficacy and safety data strengthened physician confidence in the product’s use across multiple respiratory settings.

6. Durable residual demand despite generic and pricing pressure

Although BREO faces increasing generic competition and pricing pressure within the ICS/LABA category, the product continues benefiting from strong brand recognition and physician familiarity. Patient discussions on asthma forums frequently cite convenience and effective symptom control as reasons for continued use, particularly compared with twice-daily alternatives. GSK has also introduced affordability initiatives and discount programs to support ongoing patient access.

BREO ELLIPTA Recent Developments

In September 2025, Transpire Bio's ANDA for generic BREO ELLIPTA® (fluticasone furoate/vilanterol 100/25 mcg) was accepted for filing by the U.S. FDA as the first-to-file with Paragraph IV certification under the Hatch-Waxman Act. If approved, Transpire Bio will be eligible for 180 days of market exclusivity. BREO ELLIPTA reported U.S. annual sales of $2.02 billion in 2024 (IQVIA data), indicating significant commercial value at stake. The generic targets both asthma and COPD maintenance indications.

“BREO ELLIPTA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of BREO ELLIPTA for approved indication like Asthma and Chronic obstructive pulmonary disease in the 7MM. A detailed picture of BREO ELLIPTA’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the BREO ELLIPTA for approved indications. The BREO ELLIPTA market report provides insights about BREO ELLIPTA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current BREO ELLIPTA performance, future market assessments inclusive of the BREO ELLIPTA market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of BREO ELLIPTA sales forecasts, along with factors driving its market.

BREO ELLIPTA Drug Summary

BREO ELLIPTA is a once-daily combination inhalation therapy developed by GSK for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The drug combines fluticasone furoate, an inhaled corticosteroid (ICS) that reduces airway inflammation, with vilanterol, a long-acting beta2-agonist (LABA) that provides prolonged bronchodilation to improve airflow and respiratory function. Administered through the ELLIPTA dry powder inhaler device, BREO ELLIPTA is designed to enhance symptom control, reduce exacerbation frequency, and improve lung function with convenient once-daily dosing. Clinical studies have demonstrated significant efficacy in improving forced expiratory volume (FEV1), lowering exacerbation risk, and supporting long-term disease management, making it a widely used ICS/LABA therapy in chronic respiratory care. The report provides BREO ELLIPTA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the BREO ELLIPTA Market Report

The report provides insights into:

• A comprehensive product overview including the BREO ELLIPTA MoA, description, dosage and administration, research and development activities in approved indication like Asthma and Chronic obstructive pulmonary disease.
• Elaborated details on BREO ELLIPTA regulatory milestones and other development activities have been provided in BREO ELLIPTA market report.
• The report also highlights BREO ELLIPTA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The BREO ELLIPTA market report also covers the patents information, generic entry and impact on cost cut.
• The BREO ELLIPTA market report contains current and forecasted BREO ELLIPTA sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The BREO ELLIPTA market report also features the SWOT analysis with analyst views for BREO ELLIPTA in approved indications.

Methodology

The BREO ELLIPTA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BREO ELLIPTA Analytical Perspective by DelveInsight

• In-depth BREO ELLIPTA Market Assessment

This BREO ELLIPTA sales market forecast report provides a detailed market assessment of BREO ELLIPTA for approved indication like Asthma and Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted BREO ELLIPTA sales data uptil 2034.

• BREO ELLIPTA Clinical Assessment

The BREO ELLIPTA market report provides the clinical trials information of BREO ELLIPTA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

BREO ELLIPTA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

BREO ELLIPTA Market Potential & Revenue Forecast

• Projected market size for the BREO ELLIPTA and its key indications
• Estimated BREO ELLIPTA sales potential (BREO ELLIPTA peak sales forecasts)
• BREO ELLIPTA Pricing strategies and reimbursement landscape

BREO ELLIPTA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• BREO ELLIPTA Market positioning compared to existing treatments
• BREO ELLIPTA Strengths & weaknesses relative to competitors

BREO ELLIPTA Regulatory & Commercial Milestones

• BREO ELLIPTA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

BREO ELLIPTA Clinical Differentiation

• BREO ELLIPTA Efficacy & safety advantages over existing drugs
• BREO ELLIPTA Unique selling points

BREO ELLIPTA Market Report Highlights

• In the coming years, the BREO ELLIPTA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The BREO ELLIPTA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BREO ELLIPTA’s dominance.
• Other emerging products for Asthma and Chronic obstructive pulmonary disease are expected to give tough market competition to BREO ELLIPTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BREO ELLIPTA in approved indications.
• Analyse BREO ELLIPTA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted BREO ELLIPTA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of BREO ELLIPTA in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of BREO ELLIPTA? How strong is BREO ELLIPTA’s clinical and commercial performance?
• What is BREO ELLIPTA’s clinical trial status in each individual indications such as Asthma and Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BREO ELLIPTA Manufacturers?
• What are the key designations that have been granted to BREO ELLIPTA for approved indications? How are they going to impact BREO ELLIPTA’s penetration in various geographies?
• What is the current and forecasted BREO ELLIPTA market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of BREO ELLIPTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BREO ELLIPTA for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is BREO ELLIPTA? What is the duration of therapy and what are the geographical variations in cost per patient?